Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
← catalyst calendarNCT07509151 · readout in 1,836 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
420estimated
Sites
30
Countries
Australia, Canada, Turkey (Türkiye) +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-05 | actual | When the study began enrolling |
| Primary completion | 2031-08-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-04-05 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
Intervention
- Drug: Surovatamig — also filed as TNB-486, AZD0486
Primary outcomes
what the primary-completion date above is the date OFDOSRI- Number of participants with adverse events (AEs) and Serious Adverse Events (SAEs)
measured Up to 5 years
Phase III- Progression Free Survival (PFS)
measured Until disease progression or death (up to 5 years)
DOSRI- Number of participants with study intervention discontinuations, dose reductions and dose delays due to AEs
measured Up to 5 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed